Bladder cancer survival in a former industrial area in saxony-anhalt, Germany

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 75, Issue 19-20, 2012, Pages 1216-1225

  Roth, Emanuel ^a,b   Selinski, Silvia ^b   Schikowsky, Christian ^b   Seidel, Thilo ^a   Volkert, Frank ^a   Blaszkewicz, Meinolf ^b   Hengstler, Jan G ^b   Golka, Klaus ^b  

^a Paul Gerhardt Foundation   (Germany)

^b LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CARCINOGEN; GENOMIC DNA; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1;

ADULT; AGED; BLADDER CANCER; BLADDER PAPILLOMA; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; FEMALE; FOLLOW UP; GENOTYPE; GERMANY; HUMAN; INDUSTRIAL AREA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TUMOR GROWTH;

AGED; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GERMANY; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; MUTATION; OCCUPATIONAL EXPOSURE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84866646374     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287394.2012.709168     Document Type: Conference Paper

References (39)

1. Basu, S., Brown, J. E., Flannigan, G. M., Gill, J. H., Loadman, P. M., Martin, S. W., Naylor, B., Puri, R., Scally, A. J., Seargent, J. M., Shah, T., and Phillips, R. M. 2004. NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: Relationship of genotype status to NQO1 phenotype and clinical response to mitomycin C. Int. J. Oncol. 25: 921-27.
2. Bolt, H. M., Selinski, S., Dannappel, D., Blaszkewicz, M., and Golka, K. 2005. Reinvestigation of the concordance of human NAT2 phenotypes and genotypes. Arch. Toxicol. 79: 196-200.
3. Cartwright, R. A., Rogers, H. J., Barham-Hall, D., Glashan, R. W., Ahmad, R. A., Higgins, E., and Kahn, M. A. 1982. Role of N-acetyltransferase in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. Lancet 2: 842-46.
4. Castillejo, A., Rothman, N., Murta-Nascimento, C., Malats, N., García-Closas, M., Gómez-Martínez, A., Lloreta, J., Tardón, A., Serra, C., García-Closas, R., Chanock, S., Silverman, D. T., Dosemeci, M., Kogevinas, M., Carrato, A., Soto, J. L., and Real, F. X. 2009. TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int. J. Cancer 124: 608-13.
5. Chen, M., Hildebrandt, M. A., Clague, J., Kamat, A. M., Picornell, A., Chang, J., Zhang, X., Izzo, J., Yang, H., Lin, J., Gu, J., Chanock, S., Kogevinas, M., Rothman, N., Silverman, D. T., Garcia-Closas, M., Grossman, H. B., Dinney, C. P., Malats, N., and Wu, X. 2010. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in nonmuscle-invasive bladder cancer. Cancer Prev. Res. (Phila.) 3: 235-45.
6. Frey, U. H., Eisenhardt, A., Lümmen, G., Rübben, H., Jöckel, K. H., Schmid, K. W., and Siffert, W. 2005. The T393C polymorphism of the Gas gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol. Biomarkers Prev. 14: 871-77.
7. Gangawar, R., Ahirwar, D., Mandhani, A., and Mittal, R. D. 2010. Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India. Med. Oncol. 27: 159-66.
8. García-Closas, M., Malats, N., Silverman, D., Dosemeci, M., Kogevinas, M., Hein, D. W., Tardón, A., Serra, C., Carrato, A., García-Closas, R., Lloreta, J., Castaño-Vinyals, G., Yeager, M., Welch, R., Chanock, S., Chatterjee, N., Wacholder, S., Samanic, C., Torà, M., Fernández, F., Real, F. X., and Rothman, N. 2005. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366(9486): 649-59.
9. Golka, K., Abreu-Villaca, Y., Anbari Attar, R., Angeli-Greaves, M., Aslam, M., Basaran, N., Belik, R., Butryee, C., Dalpiaz, O., Dzhusupov, K., Ecke, T. H., Galambos, H., Gerilovica, H., Gerullis, H., González, P. C., Goossens, M. E., Gorgishvili-Hermes, L., Heyns, C. F., Hodzic, J., Ikoma, F., Jichlinski, P., Kang, B.-H., Kiesswetter, E., Krishnamurthi, K., Lehmann, M.-L., Martinova, I., Mittal, R. D., Ravichandran, B., Romics, I., Roy, B., Rungkat-Zakaria, F., Rydzynski, K., Scutaru, C., Shen, J. H., Soufi, M., Toguzbaeva, K., Vu Duc, T., Widera, A., Wishahi, M., and Hengstler, J. G. 2012. Bladder cancer documentation of causes: Multilingual questionnaire "Bladder Cancer Doc." Front. Biosci. (Elite Ed.) 4: 2809-22.
10. Golka, K., Goebell, P. J., and Rettenmeier, A.W. 2007. Bladder cancer: Etiology and prevention. Dtsch. Ärztebl. 104: 719-23.
11. Golka, K., Hermes, M., Selinski, S., Blaszkewicz, M., Bolt, H. M., Roth, G., Dietrich, H., Prager, H. M., Ickstadt, K., and Hengstler, J. G. 2009. Susceptibility to urinary bladder cancer: Relevance of rs9642880[T], GSTM1 0/0 and occupational exposure. Pharmacogenet. Genomics 19: 903-6.
12. Golka, K., Prior, V., Blaszkewicz, M., and Bolt, H. M. 2002. The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: A review considering ethnic differences. Toxicol. Lett. 128: 229-41.
13. Golka, K., Prior, V., Blaszkewicz, M., Cascorbi, I., Schöps, W., Kierfeld, G., Roots, I., and Bolt, H. M. 1996. Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Scand. J. Work Environ. Health 22: 332-38.
14. Golka, K., Reckwitz, T., Kempkes, M., Cascorbi, I., Blaskewicz, M., Reich, S. E., Roots, I., Sökeland, J., Schulze, H., and Bolt H. M. 1997. N-Acetyltransferase 2 (NAT2) and glutathione S-transferase μ (GSTM1) in bladder-cancer patients in a highly industrialized area. Int. J. Occup. Environ. Health 3: 105-10.
15. Golka, K., Schmidt, T., Seidel, T., Dietrich, H., Roemer, H. C., Löhlein, D., Reckwitz, T., Sökeland, J., Weistenhöfer, W., Blaszkewicz, M., and Selinski, S. 2008. The influence of polymorphisms of glutathione S-transferases M1 and M3 on the development of human urothelial cancer. J. Toxicol. Environ. Health A 71: 881-86.
16. Golka, K., Seidel, T., Dietrich, H., Roth, G., Rötzel, C., Thier, R., Geller, F., Reckwitz, T., and Schulze, H. 2005. Occupational and non-occupational risk factors in bladder cancer patients in an industrialized area located in former East Germany. Aktuelle Urol. 35: 417-22 (in German).
17. Golka, K., Selinski, S., Lehmann, M. L., Blaszkewicz, M., Marchan, R., Ickstadt, K., Schwender, H., Bolt H. M., and Hengstler J. G. 2011. Genetic variants in urinary bladder cancer: Collective power of the "wimp SNPs." Arch. Toxicol. 85: 539-54.
18. Golka, K., Wiese, A., Assennato, G., and Bolt, H. M. 2004. Occupational exposure and urological cancer. World J. Urol. 21: 382-91.
19. Gu, J., Zhao, H., Dinney, C. P., Zhu, Y., Leibovici, D., Bermejo, C. E., Grossman, H. B., and Wu, X. 2005. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin. Cancer Res. 2005 11: 1408-15.
20. Ha, Y. S., Yan, C., Jeong, P., Kim,W. T., Yun, S. J., Kim, I. Y., Moon, S. K., and Kim, W. J. 2011. GSTM1 tissue genotype as a recurrence predictor in non-muscle invasive bladder cancer. J. Korean Med. Sci. 26: 231-36.
21. Ha, Y. S., Yan, C., Lym, M. S., Jeong, P., Kim, W. T., Kim, Y. J., Yun, S. J., Lee, S. C., Moon, S. K., Choi, Y. H, and Kim, W. J. 2010. GSTT1 as a prognosticator for recurrence and progression in patients with non-muscleinvasive bladder cancer. Dis. Markers 29: 81-87.
22. Hung, R. J., Boffetta, P., Brennan, P., Malaveille, C., Hautefeuille, A., Donato, F., Gelatti, U., Spaliviero, M., Placidi, D., Carta, A., Scotto di Carlo, A., and Porru, S. 2004. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int. J. Cancer 110: 598-604.
23. Kempkes, M., Golka, K., Reich, S., Reckwitz, T., and Bolt, H. M. 1996. Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch. Toxicol. 71: 123-26.
24. Kiemeney, L. A., Thorlacius, S., Sulem, P., Geller, F., Aben, K. K., Stacey, S. N., Gudmundsson, J., Jakobsdottir, M., Bergthorsson, J. T., Sigurdsson, A., Blondal, T., Witjes J. A., Vermeulen, S. H., Hulsbergenvan de Kaa, C. A., Swinkels, D. W., Ploeg, M., Cornel, E. B., Vergunst, H., Thorgeirsson, T. E., Gudbjartsson, D., Gudjonsson, S. A., Thorleifsson, G., Kristinsson, K. T., Mouy, M., Snorradottir, S., Placidi, D., Campagna, M., Arici, C., Koppova, K., Gurzau, E., Rudnai, P., Kellen, E., Polidoro, P., Guarrera, S., Sacerdote, C., Sanchez, M., Saez, B., Valdivia, G., Ryk C., de Verdier, P., Lindblom, A., Golka, K., Bishop, D. T., Knowles, M. A., Nikulasson, S., Petursdottir, V., Jonsson, E., Geirsson, G., Kristjansson, B., Mayordomo, J. I., Steineck, G., Porru, S., Buntinx, F., Zeegers, M. P., Fletcher, T., Kumar, R., Matullo, G., Vineis, P., Kiltie, A. E., Gulcher, J. R., Thorsteinsdottir, U., Kong, A., Rafnar, T., and Stefansson, K. 2008. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat. Genet. 40: 1307-12.
25. Kiemeney, L. A., Sulem, P., Besenbacher, S., Vermeulen, S. H., Sigurdsson, A., Thorleifsson G., Stacey S. N., Gudmundsson J., Zanon C., Kostic J., Bjarnason H., Palsson, S. T., Skarphéinsson, O., Sigurjon, A. Gudjonsson, S. A., Witjes, J. A., Grotenhuis, A. J., Verhaegh, G. W., Bishop, D. T., Sak, S. C., Choudhury, A., Elliott, F., Barrett, J. H., Hurst, C., de Verdier, P., Rudnai, P., Gurzau, E., Koppova, K., Vineis, P., Polidoro, S., Guarrera, S., Sacerdote, C., Campagna, M., Placidi, D., Arici, C., Zeegers, M. P., Kellen, E., Gutierrez, B. S., Sanz-Velez, J. I., Sanchez-Zalabardo, M., Valdivia, G., Garcia-Prats, M. D., Hengstler, J. G., Blaszkewicz, M., Dietrich, H., Ophoff, R. A., Van den Berg, L. H., Alexiusdóttir, K., Kristjansson, K., Geirsson, G., Nikulasson, S., Petursdottir, V., Kong, A., Thorgeirsson, T., Mungan, N. A., Lindblom, A., van Es, M. A., S., Buntinx, F., Golka, K., Mayordomo, J. I., Kumar, R., Matullo, G., Steineck, G. D., Kiltie, A. E., Aben, K. K. H., Jonsson, E., Thorsteinsdottir, U., Knowles, M. A., Rafnar, T., and Stefansson, K. J. 2010. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat. Genet. 42: 415-19.
26. Kim, E. J., Jeong, P., Quan, C., Kim, J., Bae, S. C., Yoon, S. J., Kang, J. W., Lee, S. C., Jun Wee, J., and Kim, W. J. 2005. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: Useful determinants for clinical outcome of bladder cancer. Urology 65: 70-75.
27. Lehmann, M. L., Selinski, S., Blaszkewicz, M., Orlich, M., Ovsiannikov, D., Moormann, O., Guballa, C., Kress, A., Truß M. C., Gerullis, H., Otto, T., Barski, D., Niegisch, G., Albers, P., Frees, S., Brenner, W., Thüroff, J. W., Angeli-Greaves, M., Seidel, T., Roth, G., Dietrich, H., Ebbinghaus, R., Prager, H. M., Bolt, H. M., Falkenstein, M., Zimmermann, A., Klein, T., Reckwitz, T., Roemer, H. C., Löhlein, D., Weistenhöfer, W., Schöps, W., Beg, A. E., Aslam, M., Bánfi, G., Romics, I., Ickstadt, K., Schwender, H., Winterpacht, A., Hengstler, J. G., and Golka K. 2010. Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk. Arch. Toxicol. 84: 967-78.
28. Mittal, R. D., Singh, R., Manchanda, P. K., Ahirwar, D., Gangwar, R., Kesarwani, P., and Mandhani, A. 2008. XRCC1 codon 399 mutant allele: A risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. Cancer Biol. Ther. 7: 645-50.
29. Murta-Nascimento, C., Schmitz-Dräger, B. J., Zeegers, M. P., Steineck, G., Kogevinas, M., Real, F. X., andMalats N. 2007. Epidemiology of urinary bladder cancer: From tumor development to patient's death. World J. Urol. 25: 285-95.
30. Ovsiannikov, D., Selinski S., Lehmann M.-L., Blaszkewicz, M., Moormann, O., Hengstler, J. G., and Golka, K. 2012. Polymorphic enzymes, urinary bladder cancer risk, and structural change in the local industry. J. Toxicol. Environ. Health A 75: 557-65.
31. Rafnar, T., Vermeulen, S. H., Sulem, P., Thorleifsson, G., Aben, K. K., Witjes, J. A., Grotenhuis, A. J., Verhaegh, G. W., Hulsbergen-van de Kaa, C. A., Besenbacher, S., Gudbjartsson, D., Stacey, S. N., Gudmundsson, J., Johannsdottir, H., Bjarnason, H., Zanon, C., Helgadottir, H., Jonasson, J. G., Tryggvadottir, L., Jonsson, E., Geirsson, G., Nikulasson, S., Petursdottir, V., Bishop, D. T., Chung-Sak, S., Choudhury, A., Elliott, F., Barrett, J. H., Knowles, M. A., de Verdier, P. J., Ryk, C., Lindblom, A., Rudnai, P., Gurzau, E., Koppova, K., Vineis, P., Polidoro, S., Guarrera, S., Sacerdote, C., Panadero, A., Sanz-Velez, J. I., Sanchez, M., Valdivia, G., Garcia-Prats, M. D., Hengstler, J. G., Selinski, S., Gerullis, H., Ovsiannikov, D., Khezri, A., Aminsharifi, A., Malekzadeh, M., van den Berg, L. H., Ophoff, R. A., Veldink, J. H., Zeegers, M. P., Kellen, E., Fostinelli, J., Andreoli, D., Arici, C., Porru, S., Buntinx, F., Ghaderi, A., Golka, K., Mayordomo, J. I., Matullo, G., Kumar, R., Steineck, G., Kiltie, A. E., Kong, A., Thorsteinsdottir, U., Stefansson, K., and Kiemeney, L. A. 2011. European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum. Mol. Genet. 20: 4268-81.
32. Rioja Zuazu, J., Bandrés Elizalde, E., Rosell Costa, D., Rincón Mayans, A., Zudaire Bergera, J., Gil Sanz, M. J., Rioja Sanz, L. A., García Foncillas, J., and Berián Polo, J. M. 2007. Steroid and xenobiotic receptor (SXR), multidrug resistance gene (MDR1) and GSTs, SULTs and CYP polymorphism expression in invasive bladder cancer, analysis of their expression and correlation with other prognostic factors. Actas Urol. Esp. 31: 1107-16.
33. Roos, P. H., Golka, K., and Hengstler, J. G. 2008. Predictive biomarkers and signatures in urinary bladder cancer. Curr. Opin. Mol. Ther. 10: 243-50.
34. Rothman, N., Garcia-Closas, M., Chatterjee, N., Malats, N., Wu, X., Figueroa, J. D., Real, F. X., Van Den Berg, D., Matullo, G., Baris, D., Thun, M., Kiemeney, L. A., Vineis, P., De Vivo, I., Albanes, D., Purdue, M. P., Rafnar, T., Hildebrandt, M. A., Kiltie, A. E., Cussenot, O., Golka, K., Kumar, R., Taylor, J. A., Mayordomo, J. I., Jacobs, K. B., Kogevinas, M., Hutchinson, A., Wang, Z., Fu, Y. P., Prokunina-Olsson, L., Burdett, L., Yeager, M., Wheeler, W., Tardón, A., Serra, C., Carrato, A., García-Closas, R., Lloreta, J., Johnson, A., Schwenn, M., Karagas, M. R., Schned, A., Andriole, G., Jr., Grubb, R. 3rd, Black, A., Jacobs, E. J., Diver, W. R., Gapstur, S. M., Weinstein, S. J., Virtamo, J., Cortessis, V. K., Gago-Dominguez, M., Pike, M. C., Stern, M. C., Yuan, J. M., Hunter, D. J., McGrath, M., Dinney, C. P., Czerniak, B., Chen, M., Yang, H., Vermeulen, S. H., Aben, K. K., Witjes, J. A., Makkinje, R. R., Sulem, P., Besenbacher, S., Stefansson, K., Riboli, E., Brennan, P., Panico, S., Navarro, C., Allen, N. E., Bueno-de-Mesquita, H. B., Trichopoulos, D., Caporaso, N., Landi, M. T., Canzian, F., Ljungberg, B., Tjonneland, A., Clavel-Chapelon, F., Bishop, D. T., Teo, M. T., Knowles, M. A., Guarrera, S., Polidoro, S., Ricceri, F., Sacerdote, C., Allione, A., Cancel-Tassin, G., Selinski, S., Hengstler, J. G., Dietrich, H., Fletcher, T., Rudnai, P., Gurzau, E., Koppova, K., Bolick, S. C., Godfrey, A., Xu, Z., Sanz-Velez, J. I., D. García-Prats, M., Sanchez, M., Valdivia, G., Porru S., Benhamou S., Hoover, R. N., Fraumeni, J. F., Jr., Silverman, D. T., and Chanock, S. J. 2010. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet. 42: 978-83.
35. Sakano, S., Kumar, R., Larsson, P., Onelöv, E., Adolfsson, J., Steineck, G., and Hemminki, K. 2006. A single-nucleotide polymorphism in the XPG gene, and tumour stage, grade, and clinical course in patients with nonmuscleinvasive neoplasms of the urinary bladder. BJU Int. 97: 847-51.
36. Sanyal, S., Ryk, C., De Verdier, P. J., Steineck, G., Larsson, P., Onelöv, E., Hemminki, K., and Kumar, R. 2007. Polymorphisms in NQO1 and the clinical course of urinary bladder neoplasms. Scand. J. Urol. Nephrol. 41: 182-90.
37. Vineis, P., Marinelli, D., Autrup, H., Brockmoller, J., Cascorbi, I., Daly, A. J., Golka, K., Okkels, K., Risch, A., Rothman, N., Sim, E., and Taioli E. 2001. Smoking, occupation, N-acetyltransferase-2 and bladder cancer: A pooled analysis of genotyped studies. Cancer Epidemiol. Biomarkers Prev. 10: 1249-52.
38. Weistenhöfer, W., Blaszkewicz, M., Bolt, H. M., and Golka K. 2008. N-Acetyltransferase-2 and medical history in bladder cancer cases with a suspected occupational disease (BK 1301) in Germany. J. Toxicol. Environ. Health A 71: 906-10.
39. Zimmermann, A., Blaszkewicz, M., Roth, G., Seidel, T., Dietrich, H., Schutschkow, O., Bolt H. M., and Golka K. 2008. UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism in bladder cancer cases. J. Toxicol. Environ. Health A 71: 911-14.